Teva Pharmaceutical Industries Ltd., TEVA today announced the
exclusive launch of the generic equivalent to Avodart®
(dutasteride) capsules, 0.5 mg, in the United States. Dutasteride is a 5
alpha-reductase enzyme inhibitor and works by lowering production of a
hormone called dihydrotestosterone (DHT). Dutasteride capsules are used
to treat the symptoms of benign prostatic hyperplasia (BPH) in men with
an enlarged prostate.
Teva was first to file and expects to be exclusive for several weeks.
Avodart® (dutasteride) capsules, marketed by GlaxoSmithKline,
had annual sales of approximately $467 million in the United States,
according to IMS data as of July 2015.
About Dutasteride
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in